Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

Published

Journal Article

A prospective diagnostic study was designed to determine the ability of thin-section contrast-enhanced computed tomography (CT) to predict the resectability of malignant neoplasms of the pancreatic head. Patients with a presumed resectable pancreatic neoplasm referred during a 21-month period were studied with abdominal CT performed at 1.5-mm section thickness and 5-mm slice interval during the bolus phase of intravenous contrast enhancement. CT criteria for resectability included the absence of extrapancreatic disease, no evidence of arterial encasement, and a patent superior mesenteric-portal venous confluence. Of 145 patients evaluated, 42 were considered to have resectable tumors by CT criteria, and 37 (88%) underwent potentially curative pancreaticoduodenectomy. Six patients were found to have a microscopically positive retroperitoneal resection margin; no patient had a grossly positive resection margin. Five (12%) of 42 patients were found at laparotomy to have unresectable, locally advanced or metastatic tumors. Thin-section contrast-enhanced CT is an essential component of the preoperative evaluation for pancreaticoduodenectomy and can prevent needles laparotomy in most patients with locally advanced or metastatic disease.

Full Text

Duke Authors

Cited Authors

  • Fuhrman, GM; Charnsangavej, C; Abbruzzese, JL; Cleary, KR; Martin, RG; Fenoglio, CJ; Evans, DB

Published Date

  • January 1, 1994

Published In

Volume / Issue

  • 167 / 1

Start / End Page

  • 104 - 111

PubMed ID

  • 7906097

Pubmed Central ID

  • 7906097

International Standard Serial Number (ISSN)

  • 0002-9610

Digital Object Identifier (DOI)

  • 10.1016/0002-9610(94)90060-4

Language

  • eng

Conference Location

  • United States